Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis
Discussion The purpose of this secondary analysis was to determine the quality of dietary intake, independent of quantity, in individuals using a GLP-1RA
It is recommended that patients taking Trulicity or another GLP-1 agonist, weigh the benefits of using the medication against the potential risks, particularly when using the drug for a non-diabetic condition such as weight loss
Recent phase 2 and phase 3 clinical trials have established the therapeutic value of various GLP-1 RAs in improving liver histology and metabolic parameters in patients with MASH
Smoking, using mouthwash with alcohol, or consuming hot beverages shortly before dosing can all affect the oral mucosa
Table 1 Efficacy of DPP-4 inhibitors in the clinical phase III programmes with at least 52 weeks duration as add on therapy to metformin compared to sulfonylureas